Selegiline and blood pressure in patients with Parkinson's disease

Acta Neurologica Scandinavica

Volumn 115, Issue 2, 2007, Pages 104-108

  Pursiainen, V ^a,c   Korpelainen, T J ^b   Haapaniemi, H T ^b   Sotaniemi, A K ^b   Myllyla V V ^b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b PEIJAS HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Autonomic nervous system; Blood pressure; Motor fluctuations; Parkinson's disease; Selegiline

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART RATE; HUMAN; MALE; ORTHOSTATIC BLOOD PRESSURE; PARKINSON DISEASE; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSTURE; SELEGILINE;

EID: 33845895520     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00742.x     Document Type: Article

References (29)

1. HAAPANIEMI TH, PURSIAINEN V, KORPELAINEN JT, HUIKURI HV, SOTANIEMI KA, MYLLYLÄ VV. Ambulatory ECG and analysis of heart rate variability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:305-10.
2. PURSIAINEN V, HAAPANIEMI TH, KORPELAINEN JT, HUIKURI HV, SOTANIEMI KA, MYLLYLÄ VV. Circadian heart rate variability in Parkinson's disease. J Neurol 2002;249:1535-40.
3. GOLDSTEIN DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76.
4. JOST WH. Autonomic dysfunction in idiopathic Parkinson's disease. J Neurol 2003;250(Suppl. 1):I28-30.
5. TURKKA JT, TOLONEN U, MYLLYLÄ VV. Cardiovascular reflexes in Parkinson's disease. Eur Neurol 1987;26:104- 12.
6. GOLDSTEIN DS, HOLMES C, LI ST, BRUCE S, METMAN LV, CANNON RO 3RD. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000;133:338-47.
7. HAAPANIEMI TH, KALLIO MA, KORPELAINEN JT et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. J Neurol 2000;247:868-74.
8. MYLLYLÄ VV, SOTANIEMI KA, VUORINEN JA, HEINONEN EH. Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand Suppl 1991;136:70-2.
9. MYLLYLÄ VV, SOTANIEMI K, MÄKI- ILOLA O, RINNE UK, HEINONEN EH. Role of selegiline in combination therapy of Parkinson's disease. Neurology 1996;47:S200-9.
10. TURKKA JT, SUOMINEN K, TOLONEN U, SOTANIEMI K, MYLLYLÄ VV. Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Neurology 1997;48:662-7.
11. CHURCHYARD A, MATHIAS CJ, PHIL D, LEES AJ. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 1999;14:246-51.
12. HEITTERACHI E, LORD SR, MEYERKORT P, MCCLOSKEY I, FITZPATRICK R. Blood pressure changes on upright tilting predict falls in older people. Age Ageing 2002;31:181-6.
13. DANIEL SE, LEES AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165- 72.
14. HOEHN MM, YAHR MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
15. FAHN S, ELTON R. Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, Vol. 2. Florham Park, NJ: Macmillan Health Care Information, 1987:153-163, 293-304.
16. THE CONSENSUS COMMITTEE OF THE AMERICAN AUTONOMIC SOCIETY AND THE AMERICAN ACADEMY OF NEUROLOGY. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996;46:1470.
17. KUJAWA K, LEURGANS S, RAMAN R, BLASUCCI L, GOETZ CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000;57:1461-3.
18. BATTACHARYA KF, NOURI S, OLANOW CW, YAHR MD, KAUFMANN H. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord 2003;9:221-4.
19. KORCHOUNOV A, KESSLER KR, SCHIPPER HI. Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson's disease. Acta Neurol Scand 2004;109:45-51.
20. LYYTINEN J, KAAKKOLA S, GORDIN A, KULTALAHTI E, TERÄVÄINEN H. Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study. Parkinsonism Relat Disord 2000;6:215-22.
21. YAHR MD, DUVOISIN RC, SCHEAR MJ, BARRET RE, HOEHN MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-54.
22. IWASAKI S, HAMAGUCHI K, IWASAKI A, TAKAKUSAGI M, NARABAYASHI Y. Hypotensive effect of long-term levodopa in patients with Parkinson's disease. Eur Neurol 1990;30:194-9.
23. GOETZ CG, LUTGE W, TANNER CM. Autonomic dysfunction in Parkinson's disease. Neurology 1986;36:73-5.
24. EMILIEN G, MALOTEAUX JM, GEURTS M, HOOGENBERG K, CRAGG S. Dopamine receptors - physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-56.
25. JOSE PA, EISNER GM, FELDER RA. The renal dopamine receptors in health and hypertension. Pharmacol Ther 1998;80:149-82.
26. VAN DIJK JG, HAAN J, ZWINDERMAN K, KREMER B, VAN HILTEN BJ, ROOS RA. Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry 1993;56:1090-5.
27. OKA H, MOCHIO S, ONOUCHI K, MORITA M, YOSHIOKA M, INOUE K. Cardiovascular dysautonomia in de novo Parkinson's disease. J Neurol Sci 2006;241:59-65.
28. MASAKI KH, SCHATZ IJ, BURCHFIEL CM et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998;98:2290-5.
29. PARKINSON STUDY GROUP. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-8.